Your session is about to expire
← Back to Search
Fecal Microbiota Transplant for Irritable Bowel Syndrome
Study Summary
This trial studies the safety and effectiveness of FMT using donor stool with low protein breakdown and Alistipes putredinis bacteria to treat PI-IBS and high protein breakdown.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have constipation-predominant IBS.I can safely have and agree to a colonoscopy.I cannot undergo a colonoscopy with sedation due to severe bowel or medical conditions.I have chronic kidney or liver disease.My cancer is currently active.I haven't taken new probiotics, antibiotics, or NSAIDs in the last 4 weeks.I cannot undergo bowel prep due to severe bowel or medical conditions.I am not taking any medication that affects bowel movement, except for loperamide.I have a weak immune system or am taking medication that weakens it.I have a history of bleeding disorders.My IBS symptoms are moderate to severe.I have not had major abdominal surgery, except for specific minor procedures.I have been diagnosed with post-infectious IBS caused by Campylobacter.I have a diagnosed gastrointestinal condition like IBD, celiac, or colitis.
- Group 1: Donor Fecal Microbiota Transplantation Group
- Group 2: Autologous Fecal Microbiota Transplantation Group
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are geriatric individuals eligible for enrollment in this research initiative?
"This medical investigation is attempting to enroll participants aged 18 and over, yet under the age of 70."
To whom is this clinical experiment open for enrollment?
"Eligibility to join this clinical trial is contingent upon having a diagnosis of irritable bowel syndrome and being between 18-70 years old. Approximately 43 participants are expected to be enrolled in the study."
Does this experiment have any open slots for enrolment?
"The current listing on clinicaltrials.gov confirms there is no longer a search for participants in this trial, which began recruiting patients on March 1st 2023 and had its last update 17 days later. Nevertheless, 1523 other trials are actively admitting new members right now."
Are there any risks associated with Donor Fecal Microbiota Transplantation Group for those receiving the treatment?
"Donor Fecal Microbiota Transplantation Group is estimated to have a safety score of 2. This assessment was based on the fact that this clinical trial is in Phase 2, showcasing some data backing its security but no evidence confirming its efficacy."
Share this study with friends
Copy Link
Messenger